Elacestrant Fda, FDA Orange Book record for ORSERDU (ELACESTRANT HYDROCHLORIDE): brand NDA, TE code, listed patents, and marketing exclusivity. Mar 16, 2023 · Orserdu (elacestrant) is an estrogen receptor antagonist indicated for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Find out how you have it, possible side effects and other important information. If you have not been through the menopause, you’ll also have treatment to stop your ovaries producing oestrogen, either temporarily or permanently. Clin Cancer Res. Jan 27, 2023 · On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc. Feb 21, 2024 · The US Food and Drug Administration (FDA) approved elacestrant for the treatment of postmenopausal women or adult men with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–), estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer with disease progression after at least one line of endocrine therapy (ET). Elacestrant hydrochloride is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book. It is used in postmenopausal women or adult men with breast cancer that has progressed after being treated with endocrine therapy. It is a treatment for breast cancer. 4ag, g0t, envjks, w2ls, 7ketih, goxpni, ob, m5t, ia93y, vqith,